STOCK TITAN
  1. Home
  2. News
  3. ARQT

Arcutis Biotherapeutics Inc - ARQT STOCK NEWS

Welcome to our dedicated news page for Arcutis Biotherapeutics (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arcutis Biotherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arcutis Biotherapeutics's position in the market.

News
Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones
Rhea-AI Summary
Aeglea BioTherapeutics announces the appointment of Scott Burrows as CFO and Heidy Abreu King-Jones as Chief Legal Officer and Corporate Secretary. The appointments strengthen Aeglea's leadership team as they advance their inflammatory bowel disease portfolio. Jonathan Alspaugh, current President and CFO, will transition into a strategic advisory role. Mr. Burrows brings over two decades of experience in biopharma finance leadership roles, while Ms. King-Jones has a proven track record in legal and corporate roles in the biopharma industry.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.76%
Tags
management
-
News
Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report
Rhea-AI Summary
Arcutis Biotherapeutics publishes annual ESG report showcasing advancements in patient care and ethical practices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.37%
Tags
none
-
News
Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%  
Rhea-AI Summary
Arcutis Biotherapeutics launches The Cream That Can ad for ZORYVE cream, a steroid-free treatment for plaque psoriasis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.98%
Tags
none
News
Arcutis Appoints Interim Chief Financial Officer (CFO)
Rhea-AI Summary
John Smither appointed interim CFO of Arcutis Biotherapeutics, replacing Scott Burrows. Smither brings financial acumen and dermatology experience from his previous CFO roles. Burrows praised Arcutis' progress and potential for future approvals and launches. Smither led successful IPO in 2020. No concrete positive or negative business takes affecting stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News
Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Greater China and Southeast Asia
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. and Hangzhou Zhongmei Huadong Pharmaceutical Co have entered into a strategic collaboration and licensing agreement for the development, manufacture, and commercialization of topical roflumilast in Greater China and Southeast Asia. Huadong will receive an exclusive license for both the cream and foam formulations of topical roflumilast, and Arcutis will receive a $30 million upfront payment and potential milestone payments and royalties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
none
-
News
Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) achieved total revenues of $5.2 million in the second quarter of 2023, with net product revenues for ZORYVE® (roflumilast) cream 0.3% at $4.8 million, a 72% increase from the first quarter. The company reported a strong financial position with approximately $270 million in cash, cash equivalents, and marketable securities as of June 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
earnings
News
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Arcutis Biotherapeutics, Inc. has granted 38,500 restricted stock units to five newly hired employees. The stock units will vest over four years, with 25% vesting on each annual anniversary of the vesting commencement date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Arcutis to Report Second Quarter Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.84%
Tags
conferences earnings
-
News
Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark
Rhea-AI Summary
Arcutis Biotherapeutics announced that its ZORYVE cream for the treatment of plaque psoriasis is now covered as a preferred tier product on CVS Caremark's national commercial formularies, providing access to an additional 20 million commercial lives in the US. This brings the total number of commercially insured patients with access to ZORYVE to 131 million, representing 80% of covered lives in the US. The cream is a once-daily, steroid-free option that provides rapid results for both hard-to-treat and sensitive areas of the body.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.31%
Tags
none
News
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
none
Stock ARQT logo
Arcutis Biotherapeutics Inc

Nasdaq:ARQT

ARQT Rankings

#2330 Ranked by Market Cap
#5426 Ranked by Stock Gains
N/A Ranked by Dividends

ARQT Stock Data

1.16B
74.79M
2.5%
95.84%
16.75%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
Westlake Village

About ARQT

arcutis biotherapeutics, inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. its lead product candidate is arq-151, a topical cream formulation of roflumilast that is in phase iii clinical trials for the treatment of plaque psoriasis and atopic dermatitis. the company is also developing arq-154, a topical foam formulation of arq-151 for the treatment of seborrheic dermatitis and scalp psoriasis; arq-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema and other inflammatory dermatoses; and arq-255, a topical formulation of arq-252 designed to reach deeper into the skin to the postulated site of inflammation in alopecia areata. the company was formerly known as arcutis, inc. and changed its name to arcutis biotherapeutics, inc. in october 2019. arcutis biotherapeutics, inc. was founded in 2016 and is headquartered in westlake village, california.